Tissue-specific RNA expression marks distant-acting developmental enhancers. by Wu, Han et al.
Lawrence Berkeley National Laboratory
Recent Work
Title
Tissue-specific RNA expression marks distant-acting developmental enhancers.
Permalink
https://escholarship.org/uc/item/7dj4w2b7
Journal
PLoS genetics, 10(9)
ISSN
1553-7390
Authors
Wu, Han
Nord, Alex S
Akiyama, Jennifer A
et al.
Publication Date
2014-09-04
DOI
10.1371/journal.pgen.1004610
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Tissue-Specific RNA Expression Marks Distant-Acting
Developmental Enhancers
Han Wu1, Alex S. Nord1, Jennifer A. Akiyama1, Malak Shoukry1, Veena Afzal1, Edward M. Rubin1,2,
Len A. Pennacchio1,2, Axel Visel1,2,3*
1 Lawrence Berkeley National Laboratory, Berkeley, California, United States of America, 2U.S. Department of Energy Joint Genome Institute, Walnut Creek, California,
United States of America, 3 School of Natural Sciences, University of California, Merced, California, United States of America
Abstract
Short non-coding transcripts can be transcribed from distant-acting transcriptional enhancer loci, but the prevalence of
such enhancer RNAs (eRNAs) within the transcriptome, and the association of eRNA expression with tissue-specific enhancer
activity in vivo remain poorly understood. Here, we investigated the expression dynamics of tissue-specific non-coding RNAs
in embryonic mouse tissues via deep RNA sequencing. Overall, approximately 80% of validated in vivo enhancers show
tissue-specific RNA expression that correlates with tissue-specific enhancer activity. Globally, we identified thousands of
tissue-specifically transcribed non-coding regions (TSTRs) displaying various genomic hallmarks of bona fide enhancers. In
transgenic mouse reporter assays, over half of tested TSTRs functioned as enhancers with reproducible activity in the
predicted tissue. Together, our results demonstrate that tissue-specific eRNA expression is a common feature of in vivo
enhancers, as well as a major source of extragenic transcription, and that eRNA expression signatures can be used to predict
tissue-specific enhancers independent of known epigenomic enhancer marks.
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Introduction
Development and function of mammalian tissues rely on the
dynamic control of tissue-specific gene expression, a process
largely regulated by distant-acting transcriptional enhancers [1–
3]. Disruption of enhancer sequences can lead to severe
phenotypes in mouse models [4–9]. Furthermore, population-
scale genetic studies indicate that a large proportion of sequence
variants associated with human diseases affect non-coding
functions in the genome, of which enhancers are a major
category [10]. Despite their functional relevance, the genome-
scale identification of enhancers that are active in vivo in
developmental and disease processes remains challenging. In
principle, genome-wide profiling of enhancer-associated epige-
nomic marks (e.g. H3K27ac and CBP/p300) enables the
genome-scale identification of enhancers predicted to be active
in a given cell type or tissue [2,3,11–15]. However, none of these
marks is unique to enhancer regions or found at all enhancers
and ChIP-based technology has well-documented limitations with
sensitivity and specificity [3,14–16].
Recently, expression of short non-coding transcripts has
been described as a feature of many enhancers with a possible
tight correlation between cell type-specific enhancer activity
and eRNA expression levels [17–20]. Using cap analysis of
gene expression (CAGE) in a collection of human tissues
and cell type, Andersson et al. [21] identified over 40,000
candidate enhancers marked by bidirectional capped RNA
expression suggesting that RNA transcription can provide a
complementary approach for de novo enhancer discovery.
Anecdotal evidence suggests a functional requirement for such
eRNAs in enhancer-mediated gene regulation [22,23]. Re-
gardless of the molecular mechanisms underlying eRNA-
mediated regulatory functions, the prevalence of eRNA
transcription at the whole transcriptome level in vivo and
whether eRNA expression signatures can potentially be used as
an independent mark for in vivo enhancer discovery remain
poorly explored.
In this study, we compare eRNA expression profiles determined
via total RNA sequencing across developmental mouse tissues and
demonstrate highly tissue-specific genome-wide expression signa-
tures of eRNAs in vivo. We find that eRNA expression globally
correlates with tissue-specific enhancer activity and that RNAs
transcribed from in vivo enhancers constitute a major proportion
of tissue-specifically expressed non-coding RNAs. Finally, we
demonstrate through application of reporter assays in transgenic
mice that differential expression of eRNAs can correctly predict
tissue-specific in vivo enhancer activities independent of other
chromatin-associated marks.
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Results
Tissue-specific eRNA expression in developing tissues
To test the hypothesis that eRNA transcription marks active in
vivo enhancers in a tissue-specific manner, we first measured
eRNA expression from 15 intergenic enhancers active in mouse
embryonic forebrain or limb buds that were randomly selected
from a larger collection of previously identified in vivo enhancers
[24]. We assessed eRNA expression from each enhancer by
quantitative RT-PCR across three different embryonic mouse
tissues including forebrain, limb, and heart as a negative control
(Figure 1). While baseline expression of each eRNA was detected
in all three tissues, in 80% of cases eRNAs from tissue-specific
enhancers showed highest expression in the predicted tissue
compared with the other two tissues (12/15; p = 0.0006, Fisher’s
exact test), suggesting that eRNAs are commonly expressed from
tissue-specific developmental enhancers with a quantitative
relationship between eRNA transcription and tissue-specific
enhancer activity.
To study eRNA expression from in vivo enhancers beyond this
small-scale qPCR screen, we examined genome-wide total RNA
transcription in embryonic heart and limb, two tissues with
different developmental origins and trajectories, and with diver-
gent in vivo enhancer landscapes as assessed by epigenomic marks
[25–27]. We extracted total RNA from limb and heart tissues
microdissected at mouse embryonic day [E] 11.5. Following
ribosomal RNA depletion, we used a strand-specific total RNA
sequencing protocol to generate more than 200 million sequencing
reads from each tissue (see Methods, Table S1). While the
majority of sequencing reads (53% in heart, 60% in limb) mapped
to annotated mouse cDNA sequences, a considerable proportion
(38% in heart, 30% in limb) mapped to introns as well as
intergenic regions, consistent with a possible association with in
vivo enhancers. Examination of individual genomic loci contain-
ing known enhancers revealed examples of bidirectional tissue-
specific eRNA expression from validated intergenic and intragenic
enhancers consistent with their in vivo activity (Figure 2A and
Figure S1). These results indicate widespread transcription
from non-coding sequences in vivo and anecdotally support
correlation of in vivo enhancer activity with tissue-specific eRNA
transcription.
Expression of eRNA correlates with enhancer activity
In order to assess tissue-specific eRNA expression more
systematically, we examined eRNA expression associated with a
large collection of in vivo-validated tissue-specific enhancers
[24,26,28] (http://enhancer.lbl.gov). To avoid confounding
factors arising from the presence of pre-mRNAs, we restricted
this analysis to intergenic in vivo enhancers (see Methods). We
examined a total of 145 such enhancers that are active in heart
or limb. In general, enhancers were substantially enriched in
uniquely mapped reads, and they were nine times as likely as
random non-coding regions to contain ten or more independent
reads within 1 kb of the enhancer midpoint (p = 5.5E-108 based
on background distribution; see Table S2 and Methods).
While 41% of enhancers met this stringent threshold, overall
92% of enhancers showed evidence of at least weak transcrip-
tion ($1 uniquely mapped reads; p = 2.3E-15 based on
background distribution, see Table S2 and Methods).
Consistent with our small-scale sampling of enhancers by
quantitative PCR (Figure 1), 79% of heart enhancers and
83% of limb enhancers showed higher eRNA expression in the
tissue where enhancer activity was observed in vivo (Fig-
ure 2B; p,1028, Fisher’s exact test). We next examined tissue-
derived RNA signatures at intergenic regions enriched for
enhancer-associated p300 and H3K27ac epigenomic marks
[27,29] from the same tissues (see Methods). Similar to known
in vivo enhancers, eRNA transcription was highly enriched
around the center regions defined by ChIP-Seq, and tissue-
specific eRNA expression patterns correlated with the predicted
enhancer activity based on tissue-specific p300 or H3K27ac
signature in the same tissues (Figure 2C–F; See Methods).
This global correlation between tissue-specific eRNA expression
and enhancer activity corroborates previous observations
derived from CAGE analysis of human cell types and tissues
[21] and supports the possibility that eRNA expression profiling
from tissues may provide an effective approach for identifying
tissue-specific in vivo enhancers.
De novo discovery of tissue-specific non-coding RNA
expression
To explore the potential of eRNA profiling for de novo
enhancer discovery, we first used a sliding window approach to
identify candidate intergenic regions enriched for RNA expres-
sion. Known coding and intronic regions and unannotated
transcripts were removed, which led to the identification of
3,422 and 3,775 intergenic regions in heart and limb,
respectively, that showed marked RNA expression at a
conservatively chosen threshold of $10 uniquely mapped reads
(see Methods; Figure S2A–B and Table S2). These regions
included 834 heart-specific and 1,078 limb-specific loci (tissue-
specifically transcribed regions, TSTRs) that were differentially
expressed in these two tissues (Figure 3A–B and Table S3).
Most of these ,2,000 TSTRs were located distal to the nearest
transcription start site (Figure S2C). There is substantial
overlap between TSTRs identified from developing mouse
tissues in this study and candidate transcription start sites (TSSs)
captured by CAGE from mouse cells and tissues [30]. Overall,
45% of heart TSTRs and 55% of limb TSTRs overlap with at
least one CAGE-derived TSS candidate. This represents a
strong enrichment compared to random control sequences (8%
and 8.3%, respectively; p,4.3E-68, Fisher’s exact test, see
Methods), but also indicates that large numbers of additional
Author Summary
Up to 80% of mammalian genomes are actively tran-
scribed, producing large numbers of non-coding RNAs
without known functions. One particularly exciting cate-
gory of such non-coding transcripts are the recently
discovered enhancer RNAs (eRNAs) transcribed from
distant-acting enhancer elements. Studies in cell-based
paradigms suggest a functional requirement for such
eRNA in enhancer-mediated gene regulation. In this study,
we explored the in vivo expression dynamics of tissue-
specific non-coding RNAs in embryonic mouse tissues via
in-depth transcriptome profiling. Our results suggest that
enhancers may be a predominant function associated with
differentially expressed non-coding loci across developing
tissues, and that differential eRNA expression signatures
from total RNA-Seq can be used to identify uncharacter-
ized tissue-specific in vivo enhancers independent of
known epigenomic marks. Our results highlight the
widespread and potentially important role of eRNAs in
orchestrating gene expression and the necessity for
functional studies in interpreting genome-wide enhancer
predictions.
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enhancer candidates were identified by analysis of ex vivo tissue
at relevant developmental stages. Tissue-specific expression of a
panel of 22 candidate TSTRs was tested and in all cases
confirmed by quantitative RT-PCR (Figure 3C–D, see Meth-
ods), demonstrating that these RNA-seq data sets accurately
identified non-coding TSTRs across tissues.
TSTRs are associated with candidate in vivo enhancers
To assess whether these TSTRs may represent in vivo enhancers,
we first examined their evolutionary sequence constraint, a feature
associated with many distant-acting enhancers [25,31,32]. We
found that 69% and 73% of TSTRs in heart and limb, respectively,
overlap with elements under evolutionary constraint as compared to
Figure 1. Tissue-specific eRNA expression at a subset of tissue-specific in vivo enhancers. (A) The expression of eRNAs was quantified by
RT-PCR for 8 randomly selected known limb enhancers in three tissues. (B) Tissue-specific eRNA expression from 7 known forebrain-specific
enhancers. The expression of eRNAs were quantified by RT-PCR for 7 randomly selected forebrain enhancers in three tissues. Results from triplicate
experiments were plotted (forebrain: blue; heart: red; limb: green). Error bars represent SEM. Representative LacZ-stained embryos at E11.5 from
transgenic assays for individual elements are shown at the bottom. Arrowheads indicate reproducible LacZ staining patters in limb (green) or
forebrain (blue).
doi:10.1371/journal.pgen.1004610.g001
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28% and 27% of random control sequences (p,2.0E-62, Fisher’s
exact test; Figure 4A and Figure S2D). Additionally, heart
TSTRs are enriched near genes critical for cardiovascular and heart
development, whereas limb TSTRs are enriched near genes
involved in muscle tissue development and limb development/
morphogenesis (Table 1). Heart and limb TSTRs are also
enriched for different sets of transcription factor binding motifs
related to development of the respective tissues compared with
random genomic sequences (Table S5 and Table S6). Finally, we
compared tissue-specific TSTR expression with mRNA levels of
nearby genes in two tissues (see Methods). The strongest
correlation was observed between TSTRs and their nearest genes
(Pearson correlation: R=0.68 for heart, R=0.55 for limb), and
decreased substantially for more distant genes (Figure 4B). These
results support that TSTRs may represent regulatory elements
coordinating the transcription of nearby genes.
To evaluate the overlap of TSTRs with enhancer-associated
epigenomic marks, we examined p300 and H3K27ac enrichment
(Figure 4C–D). We find that 36% and 46% of heart and limb
TSTRs are marked by p300 and/or H3K27ac. TSTRs with and
without epigenomic enhancer marks show similar expression level
and substantial evolutionary constraint (Figure 4A and Figure
S3A–B). However, the transcription of TSTRs with enhancer
marks tends to be more balanced in both directions, whereas
Figure 2. Global eRNA expression profiles. (A) Tissue- and strand-specific eRNA expression around a known heart enhancer (hs1670). Scales
corresponding to read count are shown on the left. Genomic region cloned for the transgenic reporter assay is indicated by the green bar.
Representative LacZ-stained embryos at E11.5 from transgenic assays for element hs1670 are shown at the bottom. Red arrowheads indicate
reproducible LacZ staining pattern in heart. (B) Differential eRNA expression at known heart- or limb-specific enhancers correlates with the tissue-
specificity of in vivo enhancer activities. Log2-transformed expression fold-changes of eRNAs arising from heart- (red) or limb-specific (cyan)
enhancers are plotted against their associated p-value for each fold change (seeMethods). (C–F) Cumulative strand-specific eRNA expression across
candidate enhancers in a 10 kb window centered on p300 (C/D) or H3K27ac (E/F) ChIP-Seq peaks from the respective tissue. Sequencing reads
mapped to forward strand (red in heart, blue in limb) or reverse strand (pink in heart, cyan in limb) are displayed separately.
doi:10.1371/journal.pgen.1004610.g002
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TSTRs marked by tissue-specific RNAs only are more biased
toward one direction (Figure S3C–D). In addition, TSTRs
negative for p300 and/or H3K27ac are more distal to the nearest
transcription start sites (Figure S3E). These results indicate a
substantial overlap of extragenic TSTRs with enhancer-like
regions. However, this does not exclude the possibility that subsets
of the observed TSTRs represent other classes of regulatory
elements or unannotated non-coding loci.
Transgenic validation of enhancer predictions based on
TSTRs
To directly assess the potential of TSTRs identified by
transcriptome profiling for the de novo discovery of tissue-specific
in vivo enhancers, we used a transgenic mouse enhancer assay
previously shown to reliably capture in vivo enhancer activity
[25,27,33]. In an initial retrospective comparison, we found that
heart- or limb-specific TSTRs overlap with 12 tested elements that
had previously been examined due to increased conservation or
enhancer associated epigenomic marks [24]. Of these elements, 9/
12 (75%) were annotated as tissue-specific positive enhancers in
vivo (Table S7, http://enhancer.lbl.gov). Next, we performed
transgenic mouse assays for another set of 19 TSTRs that had not
previously been tested (Table S8) and exhibited tissue-specific
RNA expression. This panel included elements both with and
without detectable p300 and/or H3K27ac signal in ChIP-Seq
experiments (Table S8) that were chosen blind to the identity of
nearby genes. Mouse genomic DNA for individual TSTRs with up
to 2 kb of flanking sequence was cloned upstream of a minimal
heat shock promoter fused to a lacZ reporter gene and transgenic
mice were assayed by whole-mount staining for the expression of
lacZ reporter at E11.5 [25] (see Methods). Only elements that
drove reproducible reporter gene expression pattern in at least
three embryos were considered positive enhancers. In total, 8/19
Figure 3. De novo identification of tissue-specifically transcribed regions. Dot plot showing all TSTRs identified by total RNA-Seq from heart
(A) and limb (B) E11.5 tissues. Cyan and red dots indicate limb- or heart-specific TSTRs (p,0.01). Grey dots indicate RNA peaks without significant
expression differences between the two tissues. RPKM,229 were arbitrarily set to 229 for visualization purposes (see Methods). A total of 22
candidate TSTRs were selected from heart (C) or limb (D) TSTRs. Tissue-specific RNA expression were quantified by RT-PCR by using total RNA samples
from heart or limb tissues at E11.5 (see Methods). Error bars represent SEM.
doi:10.1371/journal.pgen.1004610.g003
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(42%) candidate enhancers predicted by tissue-specific RNA
expression functioned as positive enhancers in vivo (Figure 5,
Table S8 and Figure S4). In all cases, the observed tissue-specific
in vivo enhancer activity was consistent with the tissue specificity
of the corresponding TSTR. As representative examples, trans-
genic whole-mount embryos and transverse sections for elements
mm1052, mm1018, mm1054 and mm1064 are shown in
Figure 5. In these examples, reproducible LacZ reporter
activities were detected in both atrial and ventricular regions of
the heart (Figure 5A–C) and anterior regions of the fore- and
hindlimb (Figure 5D). Combining the results from newly
performed enhancer assays and retrospective comparisons with
pre-existing in vivo data sets, 17 of 31 TSTRs (55%) represented
in vivo enhancers, and for 15 of these 17 enhancers (88%) the
tissue specificity of eRNA expression correctly predicted the in
vivo enhancer activity patterns. These results support the general
utility of eRNA profiling as an informative mark for in vivo
enhancer prediction.
Discussion
Recent large-scale transcriptome studies suggest that up to 80%
of mammalian genomes may be actively transcribed [34–37].
While many of these transcripts show differential expression
signatures across cell types and tissues, the majority of non-coding
transcripts have not been associated with in vivo functions. In the
present study, we explored the in vivo expression dynamics of
tissue-specific non-coding RNAs using a total RNA-Seq strategy
that captures both coding and non-coding transcripts [18]. Our
results suggest that the majority of enhancers show evidence of
tissue-specific eRNA transcription. In addition, de novo identified
tissue-specifically transcribed non-coding regions (TSTRs) showed
major characteristics of canonical enhancers. These results
indicate that enhancers are a predominant function associated
with differentially expressed non-coding loci across developing
tissues.
CAGE analysis from human cell lines and tissues showed that
incorporating enhancer expression data can increase the valida-
tion rate of ENCODE enhancer predictions and that bidirectional
capped RNA signatures can in principle be used to identify de
novo cell-specific enhancers [21]. However, in the absence of
sizable in vivo validation data sets, the quantitative correlation
between tissue-specific eRNA expression and in vivo enhancer
activity in mammalian developmental processes has remained
unclear [21]. We have tested a set of 19 candidate enhancers
predicted by tissue-specific RNA expression in transgenic mouse
assays and 42% showed reproducible enhancer activity in vivo,
demonstrating the general utility of eRNA-based enhancer
prediction in a developmental mammalian system. Of note, two
of the tissue-specific enhancers reported in this study (mm1052
and mm1061) did not overlap with any CAGE peaks collected
from 399 mouse samples [30] despite the scope of the tissue and
cell type panels examined in these previous studies. Considering
the dynamics of the enhancer landscape in developing tissues and
organs [29], it appears likely that many additional enhancers
active during development will be identifiable by whole tran-
scriptome analysis of tissues across different developmental stages.
While a substantial proportion of extragenic transcription
appears linked to enhancer activity, our observation of several
TSTRs that were not active in the transgenic enhancer reporter
assays supports the hypothesis that eRNA-like transcripts can also
originate from other non-coding elements, such as inactive
Figure 4. Intergenic regions marked by tissue-specific RNA expression may represent regulatory enhancer elements. (A) Fraction of
TSTRs or random control regions (all size normalized to 1 kb from center) that are under strong evolutionary constraint (30 vertebrate phastCons; see
Methods). Error bars represent 95% binomial proportion confidence interval. (B) Heatmap of Pearson correlation coefficient between tissue-
specificity of TSTRs and nearby genes (seeMethods). Genes 1 to 5 indicates the first to the fifth closest genes to the corresponding TSTR regardless
of strand. For comparison, correlation with random genes on the same chromosome as the TSTR is shown. (C and D) Heatmap of p300 binding and
H3K27ac signal within a 225 kb to +25 kb window surrounding the center of all heart TSTRs (C) or all limb TSTRs (D). Each line represents a single
TSTR for individual tissues, and color scale indicates the normalized signal from individual ChIP-Seq experiment (see Methods).
doi:10.1371/journal.pgen.1004610.g004
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enhancers. These observations are consistent with recent mech-
anistic studies on eRNAs showing that eRNA transcription
precedes the establishment of H3K4me1/2 [38], suggesting that
eRNA transcription may occur before enhancer activation.
TSTRs without supportive p300/H3K27ac marks show signifi-
cant, though slightly decreased conservation, less bi-directional
transcription, and are more distal to the nearest coding genes
(Figure S3), suggesting that they may have different biological
functions. Consistent with this observation, a larger proportion of
TSTRs with supportive p300/H3K27ac marks were active in vivo
compared to TSTRs without such marks, although this difference
was not significant at the sample size examined (p= 0.15, Fisher’s
exact test; Table S8). While the results of our study do not permit
strong conclusions about the functionality of intergenic loci that
exhibit transcription but no accompanying enhancer epigenomic
signatures, it is possible that these regions are less likely to be active
enhancers. Transcription may be occurring due to other processes
or at a different class of regulatory element than active enhancers.
Together, our data suggest that additional criteria such as bi-
directional transcription, conservation and independent enhancer
marks may further increase the performance of eRNA-based
enhancer predictions. Nonetheless, considering the overall sub-
stantial correlation between TSTRs and tissue-specific in vivo
enhancer activity, our results corroborate that short non-coding
transcripts are commonly associated with the regulation of cell
type- and tissue-specific gene expression.
Enhancer RNAs may be very unstable and sensitive to exosome
degradation [21,39], resulting in low steady-state level in cells.
This may explain why eRNAs represent a small proportion of the
transcriptome profile (Figure S2A), despite the large number of
sites from which they originate. At current sequencing depth,
many enhancers may still be missed (Figure S2B), which is
consistent with the notion that a great proportion of mammalian
genomes may be actively transcribed and cis-regulatory genomic
elements may represent major sites of extragenic non-coding
transcription [34–37,39]. Recently, Andersson et al. showed that
depletion of a co-factor of the exosome complex resulted in an
over 3-fold average increase of eRNA abundance [21]. Thus, a
combination of in-depth transcriptome profiling and exosome
depletion may provide a more sensitive method for eRNA-based
enhancer discovery.
Emerging evidence indicates that eRNA transcripts can be
required for enhancer-mediated gene activation. Targeted knock-
down of specific eRNAs has been shown to affect the expression of
enhancer target genes in cell-based assays, providing a potential
strategy for altering gene expression in experimental and
therapeutic applications [22,23,40]. Through in-depth transcrip-
tome profiling, we have shown extensive eRNA expression in
developing tissues, as well as a global correlation of eRNA
expression with tissue-specific in vivo enhancer activity. Our
results highlight the widespread and potentially important role of
eRNAs in orchestrating gene expression, providing support for the
general feasibility of eRNA-based targeting of in vivo gene
expression.
Methods
All procedures of this study involving animals were reviewed
and approved by the Animal Welfare and Research Committee at
Lawrence Berkeley National Laboratory.
Table 1. Top 10 GO biological processes enriched in genes nearby TSTRs (sorted by p-value).
Rank GO Biological Processes Binomial P-Value Binomial Fold Enrichment
Heart-specific TSTRs
1 vasculature development 1.3E-30 3.0
2 blood vessel development 9.8E-29 3.0
3 cardiovascular system development 1.5E-28 2.5
4 blood vessel morphogenesis 3.0E-26 3.1
5 regulation of myotube differentiation 8.6E-23 25.9
6 cardiac muscle tissue development 2.6E-20 4.2
7 tube development 2.5E-19 2.4
8 cardiac myofibril assembly 3.1E-19 19.1
9 positive regulation of cardioblast differentiation 1.5E-18 22.1
10 tissue morphogenesis 2.8E-18 2.4
Limb-specific TSTRs
1 regulation of skeletal muscle tissue development 1.7E-25 5.9
2 embryonic limb morphogenesis 1.7E-22 3.8
3 limb development 1.3E-20 3.1
4 regulation of striated muscle tissue development 1.8E-20 4.1
5 regulation of muscle organ development 3.5E-20 4.1
6 limb morphogenesis 1.3E-19 3.1
7 heart valve development 4.9E-19 6.5
8 negative regulation of response to DNA damage stimulus 7.5E-19 18.3
9 regulation of skeletal muscle fiber development 2.1E-18 5.7
10 regulation of cell development 1.0E-17 2.1
doi:10.1371/journal.pgen.1004610.t001
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Mouse tissue collection and RNA preparation
Embryonic heart or limb tissue was isolated from CD-1 strain
mouse embryos at E11.5 by microdissection in cold PBS [27]. A
single sample consisting of tissue pooled from multiple embryos
was analyzed for either tissue. After washing, about 1 ml TRIzol
reagent (Life Technologies, 15596-026) was added to every
100 mg of tissue sample, followed by homogenization using a
glass dounce homogenizer. Total RNA from individual tissues
were extracted following the manufacturer’s instructions. Genomic
DNA contamination was removed by using the TURBO DNA-
free kit (Applied Biosystems, AM1907) following manufacture’s
protocol, and the RNA samples were stored at 280uC before
further processing.
Illumina sequencing of total RNA
In order to perform the transcriptome analysis by Illumina
sequencing, ribosomal RNAs was removed from total RNA
(5,10 mg per reaction) by using two rounds of the RiboMinus
Eukaryote Kit for RNA-Seq (Life Technologies, A10837-08)
following the manufacturer’s instructions. The quality of total
RNA after rRNA removal was analyzed on RNA 6000 Pico chip
(Agilent, 5067-1513) to assure that rRNA contamination was less
than 30%. 100 ng total RNA after rRNA removal were used to
construct the individual sequencing libraries for Illumina sequenc-
ing. Strand-specific RNA-Seq libraries were created following in-
house protocols. Briefly, RNA samples were fragmented with
106Fragment buffer (Ambion, AM9938) to achieve an average
Figure 5. Transgenic characterization of TSTRs for tissue-specific enhancer activity. For each tested element, lateral views of whole-mount
LacZ-stained embryos at E11.5 are shown in top left panels and transverse sections through heart or limb regions are shown in the top right panels.
Arrowheads indicate reproducible LacZ staining pattern in heart (red) or limb (blue). Element ID and reproducibility of expression patterns are
indicated at the bottom of the images. Strand-specific eRNA coverage of the tested regions in heart (red) or limb (blue) is shown in the bottom
panels. Scales corresponding to read count are shown on the left of the coverage. Genomic regions cloned for the transgenic assay are indicated by
green bars. (A) Enhancer element mm1052 with activity in both atrial and ventricular regions. (B) Enhancer element mm1018 shows activity in the
right and left atrium. (C) Enhancer element 1054 with activity exclusively in the right and left ventricle. (D) Enhancer element mm1064 is active in the
anterior domains of both forelimb and hindlimb, and only transverse section of forelimb is shown as an example. RA: right atrium; LA: left atrium; RV:
right ventricle; LV: left ventricle; RFL; right forelimb; LFL: left forelimb. Transgenic results of all tested elements are available through the Vista
Enhancer Browser (http://enhancer.lbl.gov).
doi:10.1371/journal.pgen.1004610.g005
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fragment size of 200–300 nt. First strand cDNA synthesis was
performed with random hexamer and Superscript II reverse
transcriptase (Life Technologies, 18064-014). During the second
strand synthesis, dUTP was used instead of dTTP to introduce
strand-specificity. After adaptor ligation and size selection, the
second strand containing dUTP was cleaved by AmpErase UNG
(Life Technologies, N8080096). The resulting strand-specific
cDNA was subjected to 12 cycles of PCR amplification and
sequenced with HiSeq 2000 instrument. 50 sequencing cycles were
carried out.
Data processing and de novo peak calling
Raw Illumina reads (50 bp) were first filtered using the Illumina
CASAVA-1.8 FASTQ Filter module (http://cancan.cshl.edu/
labmembers/gordon/fastq_illumina_filter/). The remaining se-
quence tags were mapped back to the mouse genome (NCBI
build 37, mm9) using bowtie2 [41], and the alignments were
extended to 200 bp in the 39 direction to account for the average
length of DNA fragments. Repetitively mapped reads were
excluded from the following analysis. For de novo peak calling, a
sliding window method EnrichedRegionMaker module from
USEQ [42] was employed. For eRNA-based enhancer predic-
tions, a conservative threshold of 10 or more reads (without
considering strand specificity) was chosen based on the observation
that in retrospective comparison with in vivo validated enhancers,
40.7% of enhancers met or exceeded this expression threshold,
compared to 4.5% of random control regions (p = 5.5E-108,
Table S2). Enriched regions overlapping with refGene, mouse
mRNA, or ESTs (mm9) were also removed before the downstream
analysis. This process was performed individually for heart and
limb RNA-Seq data. To generate Figure S2B, 10% to 100% of
sequencing reads were randomly selected from the raw sequencing
data, and de novo peak calling was individually performed to
identify the enriched intergenic regions.
Among raw enriched regions, tissue-specifically transcribed
regions (TSTRs) were defined as non-coding regions with
significantly higher expression in this tissue compared with the
other tissue (p,0.01, two-proportion z-test; Figure 3A–B) [43]
with the equation shown below:
Z~(p1{p2)=
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
p0(1{p0)
N1
z
p0(1{p0)
N2
r
where p~n=N (n represents mappable reads within each TSTR
in heart or limb, and N represent the total number of mappable
reads excluding ribosomal regions in the corresponding tissue) and
p0~
n1zn2
N1zN2
. RPKM,229 were arbitrarily set to 229 for
visualization purposes in Figure 3A–B.
Candidate transcription start sites (TSSs) marked by CAGE
peaks were downloaded from http://fantom.gsc.riken.jp/5/ [30] and
extended to 1 kb each side from the peak midpoint. For each TSTR
(1 kb around the peak center), the overlapping candidate TSSs were
identified by BEDTools [44]. Random control peaks were also
generated using BEDTools with the same number and size of
sequences and excluding known genes, mouse mRNAs and ESTs.
Enhancer predictions based on epigenomic marks
We compared tissue-derived RNA signatures at intergenic
regions to enhancer-associated p300 [27] and H3K27ac marks
from the same tissues and time-point. H3K27ac ChIP-Seq datasets
are described in more detail in Nord et al. [29] and Attanasio
et al. [45]. Candidate tissue-specific intergenic enhancers were
predicted by ChIP-Seq of p300 (171 in heart, 656 in limb) or
H3K27ac (6965 in heart, 2174 in limb) as described previously
[27]. Briefly, uniquely aligned sequencing reads were extended to
300 bp in the 39 direction. Enriched regions (peaks) were identified
with MACS [46] (p#1E-5) using matched input as controls. Peaks
overlapping with repetitive regions, known genes, mouse mRNAs
and ESTs were removed for further analysis.
Enhancer RNA coverage
Summary eRNA coverage plots were generated for p300- and/
or H3K27ac-derived intergenic enhancers within a 10 kb window,
centering on the maximum ChIP-seq coverage. Using the mapped
reads, normalized mean eRNA coverage values were calculated
for 25 bp windows across the 10 kb regions scaled by total
mapped reads. For mean calculations, only the 5th–95th percentiles
were used to reduce the effect of outliers. Coverage was calculated
separately for antisense and sense reads, and as a combined value.
For the summary plots, a loess best fit line was plotted for each of
the eRNA datasets (limb and heart), separating into sense and
antisense reads (Figure 2C–F).
Conservation
Pre-computed conservation scores (phastCons scores) generated
from 30 vertebrate genome alignments were download from the
UCSC Genome Browser [47]. For each TSTR (1 kb around the
peak center), the conservation score was defined as the most highly
constrained overlapping phastCons element in the mouse mm9
genome. Random control peaks were generated using BEDTools
with the same number and size of sequences and excluding known
genes, mouse mRNAs and ESTs [44]. The percentages of TSTRs
and random control regions overlapping phastCons elements were
plotted in Figure 4A.
Heatmap generation
Tissue-specific TSTRs were classified as enriched in p300 and/
or H3K27ac if the relative ChIP-seq coverage was equal to or
greater than the 95th percentile of experiment background
coverage estimated across 1 Mb of unique sequence. After
classification, coverage heatmaps were generated for ChIP-seq
data using normalized coverage values, with input corrections.
Coverage was plotted for 25 bp windows centered on the peak
RNA coverage and extending 25 kb on either side. For plotting
purposes, coverage was centered and scaled using mean and SD in
order to compare signal across datasets. TSTRs were organized as
no H3K27ac and p300 signal, enriched in H3K27ac signal only,
enriched in p300 signal only and enriched in both marks from the
top to the bottom in Figure 4C–D.
Expression analysis
Known heart or limb enhancers were downloaded from Vista
Enhancer Browser (http://enhancer.lbl.gov). For known enhancer
regions, the expression level of individual eRNAs was defined as
the mapped sequencing reads within a 2 kb window around the
center of in vivo tested enhancers. For eRNAs only expressed in
one tissue, the mapped number of reads was arbitrarily set to 1 in
the other tissue in order to compute the absolute fold change for
plotting purposes in Figure 2B. Fold change was defined as
higher expression level divided by lower expression of each eRNA
in two tissues. For the volcano plot, y axis represents p-value for
the expression differences of each known enhancer, which was
computed by two-proportion z-test [43].
Coverage of randomly selected control regions (excluding
known genes, mRNA and ESTs) was also computed and iterated
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100 times to estimate the genome-wide background based on
normal distribution. The percentages of enhancers or the average
percentage of control regions with indicated numbers of uniquely
mapped reads in either tissue are listed in Table S2, as well as
associated p-values.
After peak calling, for each individual TSTR, normalized
RPKM (Reads Per Kilobase per Million mapped reads) was
calculated in two tissues (heart and limb) with the raw mapped
RNA-Seq data within a 2 kb window around the center of each
TSTR. Then, a tissue-specificity index was computed as (s2u)/
(s+u), in which s is the expression of TSTR in the matching tissue
and u is its expression in the other tissue. The expression of
mouse refGene (mm9) was also analyzed in the same way by
computing the RPKM across annotated cDNA regions in two
tissues.
The tissue-specific expression correlation between TSTRs and
their nearby genes was computed as described [18] with minor
modifications. Briefly, we paired each TSTR with the nearby
genes. For each set of genes with the same ranked distance to
TSTRs (the first to the fifth closest genes), genes were ranked
based on tissue-specificity indices and grouped into 20 genes per
bin. Average tissue-specificity indices from each bin were used to
compute the correlation. The Pearson correlation between nearby
genes and the corresponding TSTRs was conducted with the
statistics module in the R package (http://cran.r-project.org/).
Gene ontology analysis
Gene ontology analysis for the genes near TSTR regions was
performed by GREAT version 2.02 [48]. Enriched GO biological
processes with a binomial p-value and fold enrichment were listed
in Table 1.
Motif analysis
For TSTRs in heart and limb, enriched motifs were computed
within a 2 kb window around the center of individual TSTRs by
the motif finding module of HOMER (Hypergeometric Optimi-
zation of Motif EnRichment) [49]. Known motifs for transcription
factors with a p-value less than 1022 compared with random
genomic sequences were reporter in Table S5 and Table S6.
Directionality analysis
For directionality analysis, the expression of individual TSTRs
in sense and antisense strands was defined as the strand-specific
mapped sequencing reads within a 2 kb window around the center
of TSTRs in either heart or limb. Then the directionality index
was defined as |f2r|/(f+r), in which f is the expression of TSTR
in one strand and r is its expression in the other strand in the same
tissue.
Expression validation in vivo
Total RNA was extracted from independently collected pools of
heart or limb tissues with the same method as described before and
synthesized into cDNA by reverse transcription using the
SuperScript First-Strand Synthesis System (Invitrogen). Candidate
TSTRs for RT-PCR validations were randomly selected from the
top 30% differentially expressed regions ranked by Z scores.
Expression analysis of candidate TSTRs was carried out by real-
time PCR using gene-specific primers (Table S4) and KAPA
SYBR FAST qPCR Master Mix (KAPA Biosystems) on a Roche
LightCycler 480. All primers were designed in silico using Primer3
(http://primer3.wi.mit.edu/) and tested for amplification efficiency.
Target gene expression was calculated with the 22DDCT method
[50] and normalized to the Gapdh housekeeping gene.
In vivo transgenic validation
Candidate enhancers for in vivo testing were selected randomly
from TSTRs with a p-value less than 0.01. The tested regions
included up to 2 kb genomic DNA flanking the TSTRs on either
sides. This general transgenic procedure has been described before
[25,27]. Briefly, the selected regions were PCR amplified from
mouse genomic DNA and cloned into the Hsp68-promoter-LacZ
reporter [51,52]. Genomic coordinates and the PCR primers for
the cloned regions are listed in Table 8. The transgenic embryos
were assayed at E11.5 for expression patterns. A positive enhancer
is defined as an element with reproducible expression pattern in at
least three embryos resulting from independent transgenic
integration events [27]. For histological analysis, selected embryos
were embedded in paraffin and sectioned using standard methods.
Data access
RNA-seq data is available through GEO under accession
number GSE58157. In vivo transgenic data is available through
the Vista Enhancer Browser under the identifiers used throughout
this study (http://enhancer.lbl.gov).
Supporting Information
Figure S1 Example of intragenic eRNA expression from a
known intronic enhancer hs1430. Sequencing reads were mapped
in a strand-specific manner and displayed separately. Scales
corresponding to read count are shown on the left. Genomic
region cloned for the transgenic assay is indicated by the green
bar. Representative LacZ-stained embryos at E11.5 from
transgenic assays for element hs1430 are shown at the bottom.
Blue arrowheads indicate reproducible LacZ staining pattern in
limb.
(PDF)
Figure S2 Tissue-specific transcription from the extragenic
genome. (A) Reads obtained from each tissue-specific total
RNA-Seq experiment that unambiguously aligned to the reference
mouse genome. Enriched regions/peaks were filtered with
annotated gene (including introns, exons and UTRs), mouse
mRNA and mouse EST database. (B) Enriched intergenic
regions/peaks identified from 10% to 100% of sequencing reads
that were randomly selected from raw sequencing data (see
Methods). (C) Distance distribution between TSTRs in two
tissues and their nearest genes. (D) The phastCons conservation
scores of heart or limb TSTRs. The scores of the most highly
constrained phastCons elements in the mouse genome overlapped
with 1 kb regions flanking the center of individual TSTRs were
plotted (see Methods). For box plot in B and C, upper hinge of
the box, lower hinge of the box and horizontal line within the box
indicates 75th percentile, 25th percentile and median, respectively.
The whiskers represent the minimum and maximum values.
(PDF)
Figure S3 Characteristics of TSTRs with or without enhancer
mark(s). (A) Expression of individual TSTRs in heart and limb is
shown in box plot. For each TSTR, normalized expression
(mapped read count per kb, log10 transformed) was calculated in
two tissues (heart and limb) with the raw mapped RNA-Seq data.
(B) The fraction of TSTRs (with or without enhancer marks) or
random control regions that were under strong evolutionary
constraint. One kb flanking the center of TSTRs or control
regions were assigned the score of the most highly constrained
overlapping 30 vertebrate phastCons scores (see Methods). Error
bars represent 95% binomial proportion confidence interval. (C
and D) Cumulative plot of the directionality index (see Methods)
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in heart (C) and limb (D), respectively. (E) Distance distribution
between TSTRs in two tissues and their nearest genes. For box
plot in A and E, upper hinge of the box, lower hinge of the box
and horizontal line within the box indicates 75th percentile, 25th
percentile and median, respectively. The whiskers represent the
minimum and maximum values.
(PDF)
Figure S4 Additional TSTRs tested in transgenic assays. For
each tested element, lateral views of whole-mount LacZ-stained
embryos at E11.5 are shown in top left panels and close-ups of
LacZ-positive tissue (black dashed line) are shown in the top right
panels. Arrowheads indicate reproducible LacZ staining pattern in
limb (blue). The shape of the limb is outlined by a dashed orange
line. Element ID and reproducibility of expression patterns are
indicated at the bottom of the images. Strand-specific eRNA
coverage of tested regions in heart (red) or limb (blue) is show in
the bottom panels. Scales corresponding to read count are shown
on the left of the coverage. Genomic regions cloned for the
transgenic assays are indicated by green bars. (A) Enhancer
element mm734. (B) Enhancer element mm757. (C) Enhancer
element mm1061. (D) Enhancer element mm1063. Transgenic
results of all tested elements are available through the Vista
Enhancer Browser (http://enhancer.lbl.gov).
(PDF)
Table S1 Summary of mappability from total RNA-Seq results.
(DOCX)
Table S2 Summary of read counts uniquely mapped to in vivo
validated enhancers or control regions (100 times iteration).
(DOCX)
Table S3 List of all tissue-specific TSTRs.
(XLSX)
Table S4 List of quantitative RT-PCR primers for the validation
of tissue-specific eRNA expression.
(DOCX)
Table S5 Enriched motifs of known transcription factors among
heart-specific TSTRs.
(XLSX)
Table S6 Enriched motifs of known transcription factors among
limb-specific TSTRs.
(XLSX)
Table S7 Tested elements from Vista Enhancer Browser
overlapping TSTRs (mm9).
(DOCX)
Table S8 List of cloning primers for in vivo transgenic assays.
(DOCX)
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